90P RAS mutant colorectal cancer in Portuguese tertiary care: Molecular landscape and patterns of metastatic spreadJ.P.L. Mendes, R.J.M. Da Luz, J. Gramaça et al.|ESMO Open|2024Cited by 0
52P RAS mutation status and mutation type as potential predictive biomarkers for thrombosis in metastatic colorectal cancer: A tertiary center 12-year cohort analysisJ.L. Mendes, S. Duarte Oliveira, Rosa M. Quinta‐Ferreira et al.|ESMO Open|2024Cited by 0
52P: Does timing of immunotherapy infusion influence clinical outcomes in non-small cell lung cancer?I. Furtado, I. Guerreiro, F. Verdasca et al.|Journal of Thoracic Oncology|2025Cited by 0
66P Real-world data from fruquintinib in later line metastatic colorectal cancerF. Verdasca, J. Gramaça, A.P. Martins et al.|Annals of Oncology|2025Cited by 0
42P Comparing survival outcomes in KRAS G12 vs KRAS G13-mutated metastatic colorectal cancer (mCRC): A 13-year cohort studyRosa M. Quinta‐Ferreira, João Gramaça, Joaquim Mendes et al.|ESMO Open|2025Cited by 0